XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Shareholders' Equity and Share-based Compensation (Tables)
9 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Restricted Stock Units Activity
Time-based Restricted Stock Units (TRSUs)

The following table summarizes the Company’ TRSU activities for the nine months ended March 31, 2025:
 
Number of Time-based Restricted Stock
Units
Weighted Average
Grant Date Fair
Value Per Share
Weighted Average
Remaining
Contractual
Term (Years)
Aggregate Intrinsic Value
Nonvested at June 30, 20241,469,135 $29.13 1.66$54,901,575 
Granted614,488 $29.82 
Vested(522,441)$31.54 
Forfeited(52,233)$28.39 
Nonvested at March 31, 20251,508,949 $28.61 1.82$37,512,472 
The following table summarizes the Company’s PRSUs activities for the nine months ended March 31, 2025:

 Number of Performance-based Restricted Stock
Units
Weighted Average
Grant Date Fair
Value Per Share
Weighted Average
Remaining
Contractual Term
(Years)
Aggregate Intrinsic Value
Nonvested at June 30, 2024344,125 $30.69 1.73$12,859,951 
Granted209,750 $27.61 
Vested(133,910)$33.60 
Forfeited(10,402)$48.65 
Nonvested at March 31, 2025409,563 $27.71 2.10$10,181,736 
Summary of Stock Option Activities The following table summarizes the Company’s stock option activities for the nine months ended March 31, 2025:
Weighted
WeightedAverage
AverageRemaining
Number ofExercise PriceContractual Aggregate
SharesPer ShareTerm (in years)Intrinsic Value
Outstanding at June 30, 202410,000 $9.07 0.13$283,000 
Exercised(10,000)$9.07 $265,267 
Outstanding at March 31, 2025$0.00 0.00$0.00 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The assumptions used to estimate the fair values of common shares issued under the ESPP were as follows:
Nine Months Ended March 31,
2025
Volatility rate54.1%
Risk-free interest rate4.4%
Expected term1.3 years
Dividend yield0%
Share-based Compensation, Allocation of Recognized Period Costs
Share-based Compensation Expense
The total share-based compensation expense recognized in the Condensed Consolidated Statements of Loss for the periods presented was as follows:
Three Months Ended March 31,Nine Months Ended March 31,
2025202420252024
(in thousands)(in thousands)
Cost of goods sold$1,047 $1,424 $3,185 $3,140 
Research and development1,890 2,163 6,018 4,586 
Selling, general and administrative4,199 4,878 12,785 10,348 
$7,136 $8,465 $21,988 $18,074